NCT01265446

Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

Conditions

• Sore Throat Due to a Common Cold

Interventions

Type	Name	Description
DRUG	Lidocaine 8mg + CPC 2mg	one single dose
DRUG	Lidocaine 1mg + CPC 2mg	one single dose

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2010-12-23
• Last updated: 2013-04-24
• Results posted: 2012-07-26

Locations

1 site across 1 country: Germany